Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study

BACKGROUND: Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Watz, Henrik, Krippner, Felix, Kirsten, Anne, Magnussen, Helgo, Vogelmeier, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197315/
https://www.ncbi.nlm.nih.gov/pubmed/25280934
http://dx.doi.org/10.1186/1471-2466-14-158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197315/
https://www.ncbi.nlm.nih.gov/pubmed/25280934
http://dx.doi.org/10.1186/1471-2466-14-158

Ejemplares similares